New drug duo aims to reboot immune system against stubborn kidney cancer
NCT ID NCT06284564
Summary
This study is testing whether combining two drugs, evolocumab and nivolumab, can help control advanced kidney cancer that has stopped responding to standard immunotherapy or other targeted drugs. It will involve about 10 adults with metastatic kidney cancer to see if the combination is safe and can shrink or stabilize their tumors. The main goals are to measure tumor response and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.